trial

Efficacy, Safety, Tolerability, and Pharmacokinetics of NBI-1117568 in Adults With Schizophrenia

NCTId NCT05545111
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 2 · Completed
Enrollment 210 (actual)
Sponsored by Neurocrine Biosciences
Primary completion 2024-07-10
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 2
Status
Completed
Enrollment
210 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Quadruple
Start
2022-10-04
Primary completion
2024-07-10
Eligibility
ALL · 18 Years · 55 Years

Interventions & indications

Drugs
NBI-1117568

Sponsors

Neurocrine BiosciencesLead Sponsor

Investigators

1
Clinical Development LeadStudy Director

Sites

15 total
Little Rock, United StatesRogers, United StatesLemon Grove, United StatesPico Rivera, United StatesSan Diego, United StatesTorrance, United StatesMiami Lakes, United StatesOakland Park, United StatesGaithersburg, United StatesSt Louis, United StatesBerlin, United StatesNorth Canton, United States

Linked catalysts

1
Efficacy, Safety, Tolerability, and Pharmacokinetics of NBI-1117568 in Adults Wi — primary completion2024-07-10

Facts & assertions

4 sourced
Enrollment
210
Phase
PHASE2
Primary Completion Date
2024-07-10
Status
COMPLETED
relationships
The graph out of here
drug
NBI-1117568
drug
lead_sponsor
Neurocrine Biosciences
company
indication
Schizophrenia
indication
Schizophrenia
indication
investigator
Clinical Development Lead
person